Lab. Seminar
¾È³çÇϼ¼¿ä. À̹ø ÁÖ Åä¿äÀÏ ¼¼¹Ì³ª ¹ßÇ¥ÀÚ ÀÌÁ¤Ã¶ÀÔ´Ï´Ù.
Á¦°¡ À̹ø ÁÖ ¹ßÇ¥ÇÒ ³í¹®Àº 2021³â 5¿ù PNAS¿¡ ÃâÆÇµÈ 'Butyrate enhances CPT1A activity to promote fatty acid oxidation and iTreg differentiation'ÀÔ´Ï´Ù.
ÇöÀç Á¦°¡ ½ÇÇè¿¡ ÀÌ¿ëÇÏ°í ÀÖ´Â resistant starch´Â large intestine¿¡¼ Àå³» ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È¿¡ ÀÇÇØ fermentation µÇ´Â µ¿¾È ÃÖÁ¾ »ê¹°·Î½á butyrate¸¦ »ý»êÇÑ´Ù´Â Á¡ÀÌ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.
¶ÇÇÑ ÀÌ·¸°Ô »ý»êµÈ Butyrate´Â histone deacetylase inhibitor·Î ÀÛ¿ëÇÏ¿© foxp3 ¹ßÇöÀ» Çâ»ó½ÃÄÑ iTregÀ» ºÐȸ¦ Çâ»ó½ÃÅ°´Âµ¥ °ü¿©Çϸç, ÀÌ´Â Àå³» ¸é¿ªÀÇ homeostasis¸¦ À¯ÁöÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â Á¡ÀÌ ¾Ë·ÁÁ® ÀÖ¾ú½À´Ï´Ù.
ÇÏÁö¸¸ ¾ÆÁ÷±îÁö iTregÀÇ ºÐÈ¿¡ ÇÊ¿äÇÑ Fatty acid oxidation°ú Butyrate µÑ »çÀÌÀÇ ¿¬°ü¼ºÀº ¾ÆÁ÷ ¹àÇôÁø ¹Ù°¡ ¾ø½À´Ï´Ù.
ÇØ´ç ¿¬±¸ÁøÀº Butyrate°¡ ACSS2¿¡ ÀÇÇØ BCoA·Î processing µÇ¸ç, CPT1AÀÇ È°¼ºÀ» ÀÏÀ¸ÄÑ iTreg ºÐȸ¦ ÃËÁøÇÑ´Ù´Â Á¡À» ¹àÇû½À´Ï´Ù.
DSS-colitis model¿¡¼ ACSS2ÀÇ ¾ïÁ¦¸¦ ÅëÇØ ¿°Áõ ¹ÝÀÀÀÇ ¾ÇÈ ¹× iTreg »ý¼º Á¶ÀýÀÇ º¯È¸¦ ÅëÇØ Fatty acid oxidation °úÁ¤ µ¿¾È iTreg ºÐÈ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» °ËÁõÇÏ¿´½À´Ï´Ù.
Á¦ ½ÇÇè¿¡¼ Prebiotics·Î ÀÌ¿ëÇÏ°í ÀÖ´Â Resistant starchÀÇ fermentation °úÁ¤¿¡¼ »ý»êµÇ´Â Butyrate°¡ Àå³» ¸é¿ª ¹× Treg »ý¼º¿¡ ¾î¶°ÇÑ ¿µÇâÀ» °®´ÂÁö¿¡ °üÇØ °øºÎÇغ¸°íÀÚ ÇØ´ç ³í¹®À» ¼±Á¤ÇÏ¿´½À´Ï´Ù.
¿½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
Á¤Ã¶ ¿Ã¸²
³í¹®¸µÅ©: https://www.pnas.org/doi/10.1073/pnas.2014681118#fig03
- ´ÙÀ½±Û
- 4/30 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
- / °ü¸®ÀÚ
-
¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù.
À̹øÁÖ¿¡ Á¦°¡ ÁغñÇÑ ³í¹®ÀÇ Á¦¸ñÀº
"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity" À̸ç
¿ÃÇØ 2¿ù¿¡ Immunity¿¡ ÃâÆÇµÈ ³í¹®ÀÔ´Ï´Ù.
cDC1°ú cDC2ÀÇ ¿ªÇÒÀº ÃÖ±Ù ¸¹..
- ÀÌÀü±Û
- 4/23 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù
- / °ü¸®ÀÚ
-
¾È³çÇϼ¼¿ä ±â¼±ÀÔ´Ï´Ù.
À̹ø¿¡ Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº 2019³â Nature Communications¿¡ ÃâÆÇµÈ 'ATP released by intestinal bacteria limits the generation of protective IgA against enteropathogens'ÀÔ´Ï´Ù.
º» ³í¹®Àº eATP¸¦ °¨ÁöÇÏ´Â P2X7ÀÌ antibody Çü¼º¿¡ °ü¿©ÇÏ´Â Tfh ¼¼Æ÷ÀÇ cell death¿¡ °ü¿©..
QUICK
MENU
TOP